Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study

Lung Cancer

Volumn 99, Issue , 2016, Pages 194-199

  Wu, Hongjiang ^a   Walker, Jeremy ^a   Damhuis, Ronald A ^b   Brewster, David H ^c   Wild, Sarah H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Netherlands Comprehensive Cancer Organisation ^*  (Netherlands)

^c INFORMATION SERVICES DIVISION   (United Kingdom)

Author keywords

Diabetes; Metformin; Pleural mesothelioma; Survival

Indexed keywords

ACARBOSE; EXENDIN 4; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

AGE; AGED; ARTICLE; COHORT ANALYSIS; DIABETIC PATIENT; DISEASE DURATION; DRUG USE; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEURA MESOTHELIOMA; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS; CAUSE OF DEATH; COMPLICATION; HEALTH SURVEY; KAPLAN MEIER METHOD; LUNG TUMOR; MESOTHELIOMA; MIDDLE AGED; PLEURA TUMOR; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; METFORMIN; MIDDLE AGED; PLEURAL NEOPLASMS; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84979008574     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.07.020     Document Type: Article

References (40)

1. [1] Lacourt, A., Gramond, C., Rolland, P., Ducamp, S., Audignon, S., Astoul, P., et al. Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma. Thorax 69 (2014), 532–539.
2. [2] McDonald, J.C., Health implications of environmental exposure to asbestos. Environ. Health Perspect. 62 (1985), 319–328.
3. [3] Selikoff, I.J., Hammond, E.C., Seidman, H., Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46 (1980), 2736–2740.
4. [4] Neumann, V., Loseke, S., Nowak, D., Herth, F.J., Tannapfel, A., Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Deutsches Arzteblatt Int. 110 (2013), 319–326.
5. [5] Ruffie, P.A., Pleural mesothelioma. Curr. Opin. Oncol. 3 (1991), 328–334.
6. [6] Peto, J., Hodgson, J.T., Matthews, F.E., Jones, J.R., Continuing increase in mesothelioma mortality in Britain. Lancet 345 (1995), 535–539.
7. [7] Vandermeers, F., Neelature Sriramareddy, S., Costa, C., Hubaux, R., Cosse, J.-P., Willems, L., The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 81 (2013), 311–318.
8. [8] Swerdlow, A.J., Laing, S.P., Qiao, Z., Slater, S.D., Burden, A.C., Botha, J.L., et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br. J. Cancer 92 (2005), 2070–2075.
9. [9] Barone, B.B., Yeh, H.-C., Snyder, C.F., Peairs, K.S., Stein, K.B., Derr, R.L., et al. Postoperative mortality in cancer patients with preexisting diabetes systematic review and meta-analysis. Diabetes Care 33 (2010), 931–939.
10. [10] Barone, B.B., Yeh, H., Snyder, C.F., et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300 (2008), 2754–2764.
11. [11] Ko, C., Chaudhry, S., The need for a multidisciplinary approach to cancer care. J. Surg. Res. 105 (2002), 53–57.
12. [12] Association AD, 2012. Executive Summary. Standards of Medical Care in Diabetes—2012. Diabetes Care, 35, S4-S10.
13. [13] Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., Bost, F., Metformin in cancer therapy: a new perspective for an old antidiabetic drug. Mol. Cancer Ther. 9 (2010), 1092–1099.
14. [14] DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevent. Res. 3 (2010), 1451–1461.
15. [15] Noto, H., Goto, A., Tsujimoto, T., Noda, M., Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One, 7, 2012, e33411.
16. [16] Suissa, S., Azoulay, L., Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35 (2012), 2665–2673.
17. [17] Storozhuk, Y., Hopmans, S.N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.C., et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br. J. Cancer 108 (2013), 2021–2032.
18. [18] Troncone, M.J., Cargnelli, S.M., Pond, G., Tsiani, E., Wright, J., Steinberg, G., et al. Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer. Eur. J. Cancer, 50(Suppl. 6), 2014, 67.
19. [19] Rabin, T., Komaki, R., Raju, U., Skinner, H., Molkentine, D.P., Valdecanas, D.R., et al. Preclinical studies of metformin reveal radiosensitization for human small cell lung cancer in vitro but apparent antagonism in vivo. Int. J. Radiat. Oncol. Biol. Phys. 90 (2014), S656–S657.
20. [20] Yin, M., Zhou, J., Gorak, E.J., Quddus, F., Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 18 (2013), 1248–1255.
21. [21] Tan, B.-X., Yao, W.-X., Ge, J., Peng, X.-C., Du, X.-B., Zhang, R., et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 117 (2011), 5103–5111.
22. [22] Mazzone, P.J., Rai, H., Beukemann, M., Xu, M., Jain, A., Sasidhar, M., The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 12 (2012), 410–416.
23. [23] Ahmed, I., Ferro, A., Cohler, A., Langenfeld, J., Surakanti, S.G., Aisner, J., et al. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J. Thorac. Dis. 7 (2015), 346–355.
24. [24] Lin, J.J., Gallagher, E.J., Sigel, K., Mhango, G., Galsky, M.D., Smith, C.B., et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am. J. Respir. Crit. Care Med. 191 (2014), 448–454.
25. [25] Xu, T., Liang, G., Yang, L., Zhang, F., Prognosis of small cell lung cancer patients with diabetes treated with metformin. Clin. Transl. Oncol. 17 (2015), 819–824.
26. [26] McKnight, J.A., Morris, A.D., Cline, D., Peden, N., Fischbacher, C., Wild, S., et al. Implementing a national quality assurance system for diabetes care: the Scottish Diabetes Survey 2001–2006. Diabet. Med. 25 (2008), 743–746.
27. [27] Malik, M., Govan, L., Petrie, J., Ghouri, N., Leese, G., Fischbacher, C., et al. Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia 58 (2015), 716–725.
28. [28] Information Services Division, http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Lung-Cancer-and-Mesothelioma/#mesothelioma, (accessed 3.03.16.).
29. [29] Lee, J.H., Kim, T.I., Jeon, S.M., Hong, S.P., Cheon, J.H., Kim, W.H., The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int. J. Cancer 131 (2012), 752–759.
30. [30] Suissa, S., Dell'Aniello, S., Vahey, S., Renoux, C., Time-window bias in case-control studies: statins and lung cancer. Epidemiology 22 (2011), 228–231.
31. [31] Chen, T.-M., Lin, C.-C., Huang, P.-T., Wen, C.-F., Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J. Gastroenterol. Hepatol. 26 (2011), 858–865.
32. [32] Lega, I.C., Austin, P.C., Gruneir, A., Goodwin, P.J., Rochon, P.A., Lipscombe, L.L., Association between metformin therapy and mortality after Breast cancer: a population-based study. Diabetes Care 36 (2013), 3018–3026.
33. [33] Margel, D., Urbach, D.R., Lipscombe, L.L., Bell, C.M., Kulkarni, G., Austin, P.C., et al. Metformin use and all-cause and prostate cancer–specific mortality among men with diabetes. J. Clin. Oncol. 31 (2013), 3069–3075.
34. [34] Spillane, S., Bennett, K., Sharp, L., Barron, T.I., A cohort study of metformin exposure and survival in patients with stage I–III colorectal cancer. Cancer Epidemiol. Biomark. Prevent. 22 (2013), 1364–1373.
35. [35] Delgermaa, V., Takahashi, K., Eun-Kee, P., Giang Vinh, L., Hara, T., Sorahan, T., Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull. World Health Organ. 89 (2011), 716–724C.
36. [36] Straif, K., Benbrahim-Tallaa, L., Baan, R., Grosse, Y., Secretan, B., El Ghissassi, F., et al. A review of human carcinogens—part C: metals, arsenic, dusts, and fibres. Lancet Oncol. 10 (2009), 453–454.
37. [37] Welch, L.S., Asbestos exposure causes mesothelioma, but not this asbestos exposure: an amicus brief to the Michigan Supreme Court. Int. J. Occup. Environ. Health 13 (2007), 318–327.
38. [38] Ramazini, C., Asbestos is still with us: repeat call for a universal ban. Arch. Environ. Occup. Health 65 (2010), 121–126.
39. [39] Stayner, L., Welch, L.S., Lemen, R., The worldwide pandemic of asbestos-related disease. Annu. Rev. Public Health 34 (2013), 205–216.
40. [40] World Health Organization, Asbestos: elimination of asbesto-related diseases. 2014.